European Investor
13 Apr 2026, 19:45
Eli Lilly and Company reported positive Phase 3 results for its cancer drug Jaypirca (pirtobrutinib), showing improved outcomes for patients with chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL).
In the BRUIN CLL-322 trial, adding Jaypirca to a venetoclax-based regimen significantly extended progression-free survival compared to standard treatment alone. The study met its primary endpoint, with benefits observed across key patient groups, including those previously treated with other BTK inhibitors.
The safety profile of the combination therapy was consistent with existing data, with similar rates of adverse events between treatment arms and low discontinuation levels.
Lilly plans to present detailed findings at a medical conference and submit the data to regulators later in 2026, aiming to expand the drug’s approved indications.
The results strengthen Jaypirca’s position as a potential next-generation treatment option in blood cancers, particularly for patients requiring time-limited therapies.
PRNewswire
In the BRUIN CLL-322 trial, adding Jaypirca to a venetoclax-based regimen significantly extended progression-free survival compared to standard treatment alone. The study met its primary endpoint, with benefits observed across key patient groups, including those previously treated with other BTK inhibitors.
The safety profile of the combination therapy was consistent with existing data, with similar rates of adverse events between treatment arms and low discontinuation levels.
Lilly plans to present detailed findings at a medical conference and submit the data to regulators later in 2026, aiming to expand the drug’s approved indications.
The results strengthen Jaypirca’s position as a potential next-generation treatment option in blood cancers, particularly for patients requiring time-limited therapies.
PRNewswire